Keyphrases
Phase III Clinical Trial
100%
Androgen Deprivation Therapy
100%
Devil
100%
Overall Survival
37%
Phase II Trial
25%
Progression-free Survival
25%
Prostate Cancer Risk
25%
Non-inferiority
25%
Quality of Life
12%
Prostate Cancer
12%
Clinically Significant
12%
Cause of Death
12%
Statistical Power
12%
Quality of Life Outcomes
12%
Interim Analysis
12%
Event Rate
12%
Survival Disparities
12%
Uniform Generation
12%
Length of Follow-up
12%
Contradictory Results
12%
Hazard Ratio
12%
Absolute Difference
12%
Noninferiority Margin
12%
Non-inferiority Trial
12%
Population Survival
12%
Non-inferiority Design
12%
Superiority Trial
12%
Design Assumptions
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Androgen
100%
Overall Survival
37%
Prostate Cancer
37%
Cancer Mortality
25%
Progression Free Survival
25%
Noninferiority Trial
12%